Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding | 1.07% | $141.11M | $543.52B | 97.45% | 81 Outperform | |
| Roche Holding AG | 0.98% | $129.35M | CHF270.26B | 48.10% | 73 Outperform | |
| HSBC Holdings | 0.80% | $106.14M | $297.32B | 68.10% | 78 Outperform | |
| Shell | 0.75% | $98.97M | $212.97B | 16.23% | 78 Outperform | |
| Novartis | 0.68% | $89.20M | $282.84B | 42.16% | 80 Outperform | |
| UBS Group AG | 0.57% | $75.95M | $149.48B | 35.24% | ― | |
| SAFRAN SA | 0.55% | $72.88M | €124.18B | 28.07% | 67 Neutral | |
| Celestica | 0.55% | $72.58M | $39.71B | 162.81% | 73 Outperform | |
| AstraZeneca | 0.53% | $70.43M | $288.07B | 29.97% | 79 Outperform | |
| Toyota Motor | 0.53% | $69.93M | $283.50B | 18.90% | 81 Outperform |